Contents

Search

maribavir (Livtencity)

Indications: - post-translplantation cytomegalovirus (CMV) - treatment of adults & adolecents (>=12 years, weighing at least 35 kilograms) with post-transplant cytomegalovirus (CMV) infection/disease that does not respond to available antiviral treatment for CMV Drug interactions: - may reduce the antiviral activity of ganciclovir & valganciclovir - coadministration not recommended Mechanism of action: - cytomegalovirus pUL97 kinase inhibitor - inhibits CMV replication

General

antiviral agent

Database Correlations

PUBCHEM cid=471161

References

  1. FDA News Release. Nov 23, 2021 FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-common-type-post-transplant-infection-resistant-other-drugs
  2. Maertens J, Cordonnier C, Jaksch P et al Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. N Engl J Med 2019; 381:1136-1147 PMID: 31532960 https://www.nejm.org/doi/full/10.1056/NEJMoa1714656
  3. Mullard A FDA approves decades-old maribavir for CMV infection. Nature Reviews Drug Discovery. Dec 6, 2021 https://www.nature.com/articles/d41573-021-00208-2
  4. Wikipedia: Maribavir https://en.wikipedia.org/wiki/Maribavir